Good morning, everyone, and how are you today? We are doing just fine, thank you, courtesy of a cool breeze and a warm and shiny sun enveloping the Pharmalot campus. Our short people have departed for their destinations and our official mascot is snoozing comfortably in a corner. All of which is to say that we have a quiet moment to focus on the tasks at hand — brewing another cup of stimulation and foraging for interesting items. So time to get on with it. Here are some tidbits to help you on your own journey. Hope you have a smashing day. …

On the eve of a trial, Johnson & Johnson (JNJ) agreed to pay $9.9 million to settle a lawsuit brought by Washington state accusing it of misrepresenting the risks of pelvic mesh implants, the Associated Press writes. Attorney General Bob Ferguson sued the health-care giant in 2016, saying it failed to tell patients and doctors about the risks and occurrences of dire, sometimes irreversible complications, including urinary dysfunction, loss of sexual function, constipation, and severe pain. J&J did not admit wrongdoing. The trial had been due to start on Monday in state court.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • Online intelligence briefings
  • Frequent opportunities to engage with veteran beat reporters and industry experts
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy